MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Umeclidinium bromide

CAS No. : 869113-09-7

MCE 國(guó)際站：Umeclidinium bromide

產(chǎn)品活性：Umeclidinium bromide 是一種 mAChR 拮抗劑。Umeclidinium bromide 作用于克隆的人 M1-M5 mAChRs，K_i 為 0.05 到 0.16 nM。

研究領(lǐng)域：GPCR/G Protein  |  Neuronal Signaling

作用靶點(diǎn)：mAChR

In Vitro: In human embryonic kidney 293 cells, Umeclidinium bromide (GSK573719A) inhibits the human ether-a-go-go-related gene channel tail current in a concentration-dependent manner (IC₅₀=9.4 μM). Umeclidinium bromide, previously known as GSK573719, is a novel high-affinity specific mAChR antagonist. It is a potent agent that demonstrates slow functional reversibility at cloned human M₃ mAChRs and at endogenous mAChR in isolated human bronchus.

In Vivo: When Umeclidinium bromide (GSK573719A) is given once daily to mice for 5 consecutive days (0.025 μg intranasally), the level of inhibition on the fifth day is modestly increased above that obtained after a single administration to the same mice (60 versus 35%, respectively). After the fifth day of dosing, the mice are rested for 5 additional days, allowing bronchomotor tone to return to baseline levels. On the sixth day, the mice receive one last dose of antagonist and are once again challenged with Mch. The level of inhibition is essentially the same as that found on the first day of testing, indicating that tolerance is not evident with repeated intranasal delivery of Umeclidinium bromide. By contrast, when Umeclidinium bromide is given orally (2.0 mg/kg) to mice at a dose 100 times the ED₅₀ value (intranasal), there is no observable protection against an Mch challenge.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Parkinson's Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Clozapine N-oxide  |  Deschloroclozapine  |  Pilocarpine Hydrochloride  |  Atropine  |  Carbamoylcholine chloride  |  Scopolamine hydrobromide  |  Amitriptyline hydrochloride  |  Olanzapine  |  Methacholine chloride  |  Tiotropium Bromide  |  Xanomeline  |  Mepenzolate bromide  |  Promethazine hydrochloride  |  Propantheline bromide  |  Arecoline hydrobromide  |  Oxotremorine M iodide  |  Dronedarone  |  (S)-(+)-Dimethindene maleate  |  Pirenzepine dihydrochloride  |  DREADD agonist 21  |  Benztropine mesylate  |  Darifenacin hydrobromide  |  Tropicamide

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds